Elucida Oncology
Biotechnology, 1 Deerpark Dr, Monmouth Junction, New Jersey, 08852, United States, 1-10 Employees
Phone Number: 73********
Who is ELUCIDA ONCOLOGY
Elucida Oncology, Inc., is a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small nanoparticle CDot drug conju...
Read More
-
Headquarters: 1 Deerpark Dr, Monmouth Junction, New Jersey, 08852, United States
-
Date Founded: 2014
-
Employees: 1-10
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8011
Does something look wrong? Fix it. | View contact records from ELUCIDA ONCOLOGY
Elucida Oncology Org Chart and Mapping
Email
Phone
Similar Companies to Elucida Oncology
Aro Biotherapeutics
-
11-50
-
$ 1 Million to 5 Million
Elicio Therapeutics
-
11-50
-
$ 10 Million to 25 Million
Lexeo Therapeutics
-
11-50
-
$ 1 Million to 5 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Elucida Oncology
Answer: Elucida Oncology's headquarters are located at 1 Deerpark Dr, Monmouth Junction, New Jersey, 08852, United States
Answer: Elucida Oncology's phone number is 73********
Answer: Elucida Oncology's official website is https://elucidaoncology.com
Answer: Elucida Oncology's revenue is $5 Million to $10 Million
Answer: Elucida Oncology's SIC: 8011
Answer: Elucida Oncology has 1-10 employees
Answer: Elucida Oncology is in Biotechnology
Answer: Elucida Oncology top competitors include: Aro Biotherapeutics , Elicio Therapeutics , Lexeo Therapeutics
Answer: Elucida Oncology contact info: Phone number: 73******** Website: https://elucidaoncology.com
Answer: Elucida Oncology, Inc., is a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small nanoparticle CDot drug conjugate (CDC) platform. CDCs are designed to penetrate deeper into tumors and deliver a significantly higher payload compared to antibody drug conjugates (ADCs). This combined with greater avidity for the target antigen, longer retention in tumors with minimal systemic exposure due to rapid renal clearance confers unique Target or Clear properties. In preclinical studies, this has resulted in enhanced efficacy irrespective of antigen expression levels with reduced off-target toxicity, thereby potentially addressing the limitations of ADCs and other novel drug carriers.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month